Saúde Pública/Medicina Humanitária
[Preprint] Rápida substituição da variante B.1.1.7 (Alfa) do SARS-CoV-2 pelas variantes B.1.617.2 (Delta) e P.1 (Gama) nos Estados Unidos.
22 Jun, 2021 | 09:14hRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Comentário no Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward 🇵🇸💔Bassam Ghanem (@ABsteward) June 22, 2021
Perspectiva | COVID-19: ascensão e ascensão de Delta.
22 Jun, 2021 | 09:13hCOVID-19: The rise and rise of Delta – Sciblogs
Ivermectina é a nova hidroxicloroquina, parte 2 – “Ivermectina não deve ser usada no tratamento da COVID-19 fora do contexto de um estudo clínico.”
22 Jun, 2021 | 09:11hIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Relacionado: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance E M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials E FDA: Why you should not use Ivermectin to treat or prevent COVID-19 E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 E NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” E Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Dados da Inglaterra mostram que o risco de reinfecção por Covid-19 é baixo – “Houve 15.893 possíveis reinfecções pelo SARS-CoV-2 identificadas até 30/5/2021 na Inglaterra ao longo da pandemia, em cerca de 4 milhões de pessoas com infecções confirmadas. Isso equivale a aproximadamente 0,4% de casos de reinfecção.”
21 Jun, 2021 | 11:03hNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Relacionado: Had COVID? You’ll probably make antibodies for a lifetime – Nature E COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. E Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.
Transmissibilidade aumentada e disseminação global das variantes de preocupação do SARS-CoV-2 – “Aumentos estimados da transmissibilidade das variantes alfa 29% (95% IC: 24–33), beta 25% (95% IC: 20–30), gama 38% (95% IC: 29–48) e delta 97% (95% IC: 76–117).”
21 Jun, 2021 | 11:02h
Comentário no Twitter
NEW publication in Eurosurveillance
Increased transmissibility & global spread of #SARSCoV2 VOC & VOI
Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)
⬇️https://t.co/pmyfQMM78y pic.twitter.com/Xz3cOImRvc
— Maria Van Kerkhove (@mvankerkhove) June 17, 2021
OMS afirma que a variante delta da Covid está se tornando a variante dominante no mundo.
21 Jun, 2021 | 11:01hWHO says delta is becoming the dominant Covid variant globally – CNBC
Perspectiva | Uma bela ideia: como a COVAX decepcionou.
21 Jun, 2021 | 11:01hA beautiful idea: how COVAX has fallen short – The Lancet
Comentários no Twitter
#COVAX was meant to supply #COVID19 vaccines for all based on solidarity and equity. Instead, it relies on rich countries' willingness to share their doses—Ann Danaiya Usher tracks the ambitions and shortcomings of COVAX: https://t.co/FbAZ1D8M4j #VaccinEquity pic.twitter.com/q880pzeU1s
— The Lancet (@TheLancet) June 19, 2021
#Vaccine doses given/100 inhabitants…🤔Rich countries praising solidarity by contributing to #COVAX while making sure that there is barely any #COVID19 vaccine left to be purchased through covax.
Check also @newhumanitarian: https://t.co/K1zzM6O3on pic.twitter.com/IpH0mDJqwC
— Tim Buder (@Tim_Buder) February 10, 2021
“COVAX has delivered over 72m doses to 125 countries. But that is far less than 172m it should have delivered by now. Of the 2.1 billion COVID-19 vaccine doses administered worldwide so far, COVAX has been responsible for less than 4%"#PeoplesVaccinehttps://t.co/TZKc8YPAdJ
— Steve Jackson (@stevejacksonHN) June 20, 2021
Estudo | Parâmetros do espermograma não mudaram antes e depois da recepção de vacinas contra Covid-19 baseadas em mRNA.
21 Jun, 2021 | 10:59hSperm Parameters Before and After COVID-19 mRNA Vaccination – JAMA
Preocupado com as últimas notícias sobra a AstraZeneca? Estes 3 gráficos ajudam a compreender o risco – “Na Austrália, 2 pessoas morreram de trombose com trombocitopenia após 3,8 milhões de doses da vacina da AstraZeneca terem sido aplicadas.”
21 Jun, 2021 | 10:58hOMS alerta para o aumento da COVID-19 na África.
21 Jun, 2021 | 10:56hAfrica’s COVID-19 Surge is Expected to Worsen, Warns WHO – Health Policy Watch